(Q43854429)

27 November 2017

Pharmacokinetic drug interactions with nevirapine (English)

1 reference

27 November 2017

Pharmacokinetic Drug Interactions with Nevirapine (English)

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

22 March 2024

1 reference

David Back

1

1 reference

27 November 2017

Sara Gibbons

2

1 reference

27 November 2017

Saye Khoo

3

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

27 November 2017

http://journals.lww.com/00126334-200309011-00003

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Journal of Acquired Immune Deficiency Syndromes

22 March 2024

published in

1 reference

27 November 2017

34 Suppl 1

1 reference

27 November 2017

S8-14

1 reference

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

27 November 2017

1

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Interactions among drugs for HIV and opportunistic infections

22 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

22 March 2024

HIV-protease inhibitors

3

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Drug Metabolism and Disposition

22 March 2024

4

27

1488

Erickson

1999

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

22 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents

22 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

22 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

22 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

22 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Nelfinavir mesylate: a protease inhibitor

22 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

22 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

22 March 2024

Efavirenz

12

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

22 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

A pharmacophore for human pregnane X receptor ligands

22 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

22 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

CYP3A gene expression in human gut epithelium

22 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery

22 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

22 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

22 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Lack of pharmacokinetic interaction between nelfinavir and nevirapine

22 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users

22 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Drug treatment of lipid disorders

22 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

22 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

22 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Drug Metabolism and Disposition

22 March 2024

28

27

1194

Ramachandran

1999

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

22 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Drug Metabolism and Disposition

22 March 2024

30

18

711

Pichard

1990

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

Therapeutic drug monitoring in HIV infection: current status and future directions

22 March 2024

31

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

22 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

22 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/00126334-200309011-00003

22 March 2024

Identifiers

1 reference

release_c2abtqtx5ja77gdgyucvw5jeru

27 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c2abtqtx5ja77gdgyucvw5jeru

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference